Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Corvus Pharmaceuticals Inc

CRVS ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: BUY

Last Close

$14.89

▼ -1.65%

Market Cap $1.25B · Vol 284.11K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$1.25B

Small Cap

Div Yield

N/A

EPS Growth

-290.26%

YoY

RSI (14)

78.06

Momentum

Beta

0.87

vs Market

52W High

$26.94

44.73% below

52W Low

$4.96

200.50% above

Volume

284.11K

Avg 382.61K

P/B

9.40

Price-to-book

ROE

N/A

Return on equity

Free Float

79.15%

Public shares

Shariah Compliance8 STANDARDS

✗ Corvus Pharmaceuticals Inc (CRVS) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does CRVS pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+6.97%

-0.53%

+9.04%

-20.20%

YTD

+93.38%

+207.01%

+589.35%

+652.02%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-15,283,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-21.83% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	9.40
P/FCF	N/A
EPS Growth	-290.26%
Outstanding Shares	84.12M

Technical Indicators

50-Day SMA	$13.63
200-Day SMA	$13.31
RSI (14)	78.06
Beta	0.87
52-Week High	$26.94
52-Week Low	$4.96

Volume Today	284.11K
Avg Daily Volume (30D)	382.61K
Relative Volume	0.74x
Volatility (10D)	39.30
Volatility (30D)	47.94
Free Float	79.15%

Analyst Consensus

BUY

Current Price $14.89

Mean Target $33.14

52W Low$4.96 52W High$26.94

Current

Target

$4.96 $26.94

Current Analyst target

+122.58% upside potential · 8 analysts

Identifiers

ExchangeNasdaq

FIGIBBG009F0TGJ6

ISINUS2210151005

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 2, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. ITK, an enzyme that functions in T cell signaling and differentiation, is expressed predominantly in T cells. Its second product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine designed to disable a tumor’s ability to subvert attack by the immune system by blocking the binding of immunosuppressive adenosine in the tumor microenvironment to the A2A receptor. The Company’s third product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73.